News October 12, 2021 RayzeBio Appoints Mary Tagliaferri, M.D. to its Board of Directors and Expands Leadership Team with Rozalyn Littler as VP of Regulatory and QualityRead more ⟶ August 31, 2021 RayzeBio Expands Leadership Team with Susan Moran, M.D., as Chief Medical Officer; Kimberly Ma, M.S., as SVP of Clinical Operations; and Nicholas Smith, Ph.D., as SVP of Chemistry InnovationRead more ⟶ July 12, 2021 48Hour Discovery and RayzeBio Announce strategic Research Collaboration to Discover & Develop Novel Peptide-Based RadiopharmaceuticalsRead more ⟶ June 28, 2021 Nimble Therapeutics and RayzeBio Announce Strategic Research Collaboration to Discover & Develop Novel Peptide-Based RadiopharmaceuticalsRead more ⟶ June 15, 2021 RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for CancerRead more ⟶ April 21, 2021 RayzeBio Appoints Yi Larson to Its Board of Directors and Expands Team with Key Leadership HiresRead more ⟶ December 8, 2020 RayzeBio Completes $105M Series B Financing to Advance Targeted Radiopharmaceuticals for CancerRead more ⟶ October 14, 2020 RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer TherapeuticsRead more ⟶ August 4, 2020 PeptiDream Announces Strategic Partnership with RayzeBio for the Discovery and Development of Peptide-RadiotherapeuticsRead more ⟶
